Blair William & Co. IL Purchases 32,925 Shares of Haleon PLC Sponsored ADR $HLN

Blair William & Co. IL boosted its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 267.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 45,220 shares of the company’s stock after buying an additional 32,925 shares during the quarter. Blair William & Co. IL’s holdings in Haleon were worth $469,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. bought a new stake in Haleon during the 2nd quarter worth about $37,000. US Bancorp DE increased its stake in shares of Haleon by 5.5% in the 2nd quarter. US Bancorp DE now owns 749,052 shares of the company’s stock valued at $7,768,000 after acquiring an additional 39,235 shares during the last quarter. Country Club Bank increased its stake in shares of Haleon by 16.2% in the 2nd quarter. Country Club Bank now owns 15,469 shares of the company’s stock valued at $161,000 after acquiring an additional 2,152 shares during the last quarter. Valeo Financial Advisors LLC increased its stake in shares of Haleon by 14.0% in the 2nd quarter. Valeo Financial Advisors LLC now owns 24,148 shares of the company’s stock valued at $250,000 after acquiring an additional 2,973 shares during the last quarter. Finally, DAVENPORT & Co LLC increased its stake in shares of Haleon by 5.4% in the 2nd quarter. DAVENPORT & Co LLC now owns 294,974 shares of the company’s stock valued at $3,059,000 after acquiring an additional 15,178 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wall Street Zen cut Haleon from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Wednesday, October 8th. Barclays cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, September 16th. Finally, The Goldman Sachs Group raised Haleon from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Trading Up 3.0%

Shares of Haleon stock opened at $9.48 on Friday. Haleon PLC Sponsored ADR has a 12-month low of $8.71 and a 12-month high of $11.42. The stock has a market cap of $42.22 billion, a P/E ratio of 24.31, a P/E/G ratio of 2.69 and a beta of 0.20. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $9.41 and its 200-day moving average is $9.99.

Haleon Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Thursday, September 18th. Stockholders of record on Friday, August 15th were paid a dividend of $0.0555 per share. The ex-dividend date was Friday, August 15th. This represents a dividend yield of 190.0%. This is an increase from Haleon’s previous semi-annual dividend of $0.05. Haleon’s dividend payout ratio (DPR) is currently 28.21%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.